Literature DB >> 21050812

FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?

Richard Kim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21050812     DOI： 10.1016/S1470-2045(10)70237-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  22 in total

1.  Pre- and intraoperative variables affecting early outcomes in elderly patients undergoing pancreaticoduodenectomy.

Authors:  Sebastian G de la Fuente; Kyla M Bennett; Theodore N Pappas; John E Scarborough
Journal:  HPB (Oxford)       Date:  2011-10-12       Impact factor: 3.647

Review 2.  Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

Authors:  Jie-Er Ying; Li-Ming Zhu; Bi-Xia Liu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.

Authors:  Ling Li; Wenhua Tang; Xiaoqing Wu; David Karnak; Xiaojie Meng; Rachel Thompson; Xinbao Hao; Yongmin Li; Xiaotan T Qiao; Jiayuh Lin; James Fuchs; Diane M Simeone; Zhi-Nan Chen; Theodore S Lawrence; Liang Xu
Journal:  Clin Cancer Res       Date:  2013-10-16       Impact factor: 12.531

Review 4.  Oncolytic virotherapy for pancreatic cancer.

Authors:  Sonia Wennier; Shoudong Li; Grant McFadden
Journal:  Expert Rev Mol Med       Date:  2011-05-18       Impact factor: 5.600

5.  Nanovector-based therapies in advanced pancreatic cancer.

Authors:  Chang-Sung Tsai; John W Park; Li-Tzong Chen
Journal:  J Gastrointest Oncol       Date:  2011-09

6.  Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.

Authors:  C L Attard; S Brown; K Alloul; M J Moore
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

7.  Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

Authors:  B M Wolpin; E M O'Reilly; Y J Ko; L S Blaszkowsky; M Rarick; C M Rocha-Lima; P Ritch; E Chan; J Spratlin; T Macarulla; E McWhirter; D Pezet; M Lichinitser; L Roman; A Hartford; K Morrison; L Jackson; M Vincent; L Reyno; M Hidalgo
Journal:  Ann Oncol       Date:  2013-02-28       Impact factor: 32.976

8.  Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma.

Authors:  Brian A Boone; Herbert J Zeh; Brady K Mock; Paul J Johnson; Igor Dvorchik; Ken Lee; A James Moser; David L Bartlett; J Wallis Marsh
Journal:  HPB (Oxford)       Date:  2013-04-22       Impact factor: 3.647

9.  Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.

Authors:  M M Vickers; J Pasieka; E Dixon; S McEwan; A McKay; D Renouf; D Schellenberg; D Ruether
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

10.  Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of Apoptosis.

Authors:  Carlos J Díaz Osterman; Amber Gonda; TessaRae Stiff; Ulysses Sigaran; Malyn May Asuncion Valenzuela; Heather R Ferguson Bennit; Ron B Moyron; Salma Khan; Nathan R Wall
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.